Merck & Co Inc
MRK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Merck & Co Inc News & Analysis
stocks
A wave of US biotech IPOs may be starting - here’s why
M&A activity is bolstering IPOs within key areas of the biotech space. A GLP-1 maker and a protein biomarker detection company are the latest.
markets
Market Minute: Trade policy dominates, opportunities in global healthcare, and a local rate cut on the cards
Senior Portfolio Manager Bryce Anderson reviews the biggest market movements of the week, with Trump’s trade policy dominating again.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,417.60 | 19.80 | -0.21% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,830.08 | 162.05 | 0.63% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,862.52 | 1,255.81 | 1.91% |
| NZX 50 Index | 13,844.17 | 20.04 | 0.14% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,228.60 | 21.00 | -0.23% |
| SSE Composite Index | 3,947.91 | 7.87 | 0.20% |